Avidity Biosciences Inc
RNA37.521USD
+1.601+4.46%
交易中 （美東）報價延遲15分鐘
4.52B總市值
虧損本益比TTM
關於 Avidity Biosciences Inc 公司
Avidity Biosciences, Inc. 是一家生物製藥公司。該公司致力於提供一種稱爲抗體寡核苷酸偶聯物 (AOC) 的新型核糖核酸 (RNA) 療法。AOC 旨在將單克隆抗體的特異性與寡核苷酸療法的精確性相結合，以解決現有 RNA 療法以前無法觸及的目標和疾病。其不斷推進和擴展的管道有三個臨牀開發項目。AOC 1001 旨在治療患有 1 型肌強直性營養不良症 (DM1) 的人，並且與正在進行的 MARINA 開放標籤擴展研究 (MARINA-OLE) 一起處於 I/II 期開發階段。AOC 1044 專爲杜氏肌營養不良症患者設計，並且與 EXPLORE44 試驗一起處於 I/II 期開發階段。 AOC 1020 旨在治療面肩肱型肌營養不良症 (FSHD) 患者，目前正與 FORTITUDE 試驗一起處於 I/II 期開發階段。
公司簡介
公司代碼RNA
公司名稱Avidity Biosciences Inc
上市日期Jun 12, 2020
CEOMs. Sarah Boyce
員工數量391
證券類型Ordinary Share
年結日Jun 12
公司地址10578 Science Center Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92121
電話18584017900
網址https://www.aviditybiosciences.com/
公司代碼RNA
上市日期Jun 12, 2020
CEOMs. Sarah Boyce
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
6.69K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
6.69K
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
+105.68%
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
+0.99%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
50.00K
+100.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.64K
-1.80%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
收入明細
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
暫無數據
地區USD
名稱
營收
佔比
United States
1.57M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
12.69%
Janus Henderson Investors
9.48%
T. Rowe Price Associates, Inc.
9.30%
Wellington Management Company, LLP
8.03%
The Vanguard Group, Inc.
7.65%
Other
52.85%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
47.08%
Investment Advisor
46.95%
Hedge Fund
6.31%
Venture Capital
5.98%
Corporation
4.21%
Research Firm
2.59%
Private Equity
1.94%
Individual Investor
1.01%
Sovereign Wealth Fund
0.60%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
495
141.64M
117.51%
-2.91M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
2023Q2
328
86.81M
124.27%
-3.56M
2023Q1
328
80.46M
115.95%
-5.12M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
15.29M
12.69%
-866.01K
-5.36%
Mar 31, 2025
Janus Henderson Investors
11.43M
9.48%
+4.37M
+62.01%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.21M
9.3%
+289.32K
+2.65%
Mar 31, 2025
Wellington Management Company, LLP
9.68M
8.03%
+1.58M
+19.47%
Mar 31, 2025
The Vanguard Group, Inc.
9.22M
7.65%
-188.71K
-2.01%
Mar 31, 2025
RTW Investments L.P.
8.75M
7.26%
+814.06K
+10.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.40M
6.96%
-22.20K
-0.26%
Mar 31, 2025
Avoro Capital Advisors LLC
7.63M
6.33%
+125.00K
+1.67%
Mar 31, 2025
RA Capital Management, LP
6.30M
5.23%
--
--
Mar 31, 2025
Bristol Myers Squibb
5.08M
4.21%
--
--
Sep 30, 2024
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Global X Genomics & Biotechnology ETF
3.64%
ALPS Medical Breakthroughs ETF
2.32%
Tema Neuroscience and Mental Health ETF
1.72%
SPDR S&P Biotech ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.5%
ProShares Ultra Nasdaq Biotechnology
0.38%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
查看更多
Global X Genomics & Biotechnology ETF
佔比3.64%
ALPS Medical Breakthroughs ETF
佔比2.32%
Tema Neuroscience and Mental Health ETF
佔比1.72%
SPDR S&P Biotech ETF
佔比0.91%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.5%
ProShares Ultra Nasdaq Biotechnology
佔比0.38%
Invesco Nasdaq Biotechnology ETF
佔比0.38%
iShares Biotechnology ETF
佔比0.32%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
